Abstract Number: 0121 • ACR Convergence 2021
The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression
Background/Purpose: Fibromyalgia (FM) and major depression frequently coexist. Patients with both conditions have a worse prognosis and higher disability, and their treatment options are scarce.…Abstract Number: 0207 • ACR Convergence 2021
Treatment of Ocular Sarcoidosis: Study of 65 Patients of a Series of 384 Patients from a Single University Hospital
Background/Purpose: Ocular involvement is a relatively frequent and potentially severe complication of sarcoidosis. Oral corticosteroids (OCS) are the first-line treatment. Conventional immunosuppressive agents (cIS) and…Abstract Number: 0414 • ACR Convergence 2021
Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study
Background/Purpose: Up to 87% of patients with anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) have ear, nose and throat (ENT) involvement, which can lead to…Abstract Number: 0729 • ACR Convergence 2021
A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects
Background/Purpose: Lorecivivint (LOR), a novel intra-articular (IA) CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways, is in development as a knee osteoarthritis (OA) treatment. To…Abstract Number: 0730 • ACR Convergence 2021
Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study
Background/Purpose: Knee osteoarthritis (OA) is a painful condition leading to joint damage and impaired function. Intra-articular (IA) corticosteroid injections are frequently prescribed to treat pain.…Abstract Number: 0778 • ACR Convergence 2021
Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Juvenile-Onset Systemic Sclerosis
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a rare autoimmune disease associated with life-threatening multi-organ inflammation and fibrosis. As in adults, jSSc organ involvement includes vascular,…Abstract Number: 0781 • ACR Convergence 2021
Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…Abstract Number: 1124 • ACR Convergence 2021
Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Background/Purpose: To better understand the complex relationships between treatment and pain and physical function (PF) outcomes, we investigated a set of mediation models of osteoarthritis…Abstract Number: 1256 • ACR Convergence 2021
Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by polyarthritis of small and large joints. RA is the second most common type…Abstract Number: 1529 • ACR Convergence 2021
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…Abstract Number: 1764 • ACR Convergence 2021
Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients
Background/Purpose: HCQ is an antimalarial drug effective in the treatment of rheumatologic conditions. High blood levels, advanced age, and extended treatment duration are associated with…Abstract Number: 1815 • ACR Convergence 2021
Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
Background/Purpose: Iguratimod, also known as T-614, is a new type of small molecule compound with anti-inflammatory and immunomodulatory effects; It was listed in China(2011) and…Abstract Number: 1829 • ACR Convergence 2021
Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
Background/Purpose: Enthesitis is a recognized as a hallmark of spondyloarthrtis (SpA), including psoriatic arthritis (PsA). However, it is an underestimated disease domain in both in…Abstract Number: 098 • 2020 Pediatric Rheumatology Symposium
Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) should be considered as a polygenic autoinflammatory disease. Interleukin 1 (IL-1) has been shown to be a major mediator…Abstract Number: 003 • 2020 Pediatric Rheumatology Symposium
Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers
Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment…
- 1
- 2
- 3
- …
- 22
- Next Page »